文献速递脑血管病

脑微出血与口服抗凝的房颤急性缺血性卒中患者结局

Microbleeds and Outcome in Patients With Acute Ischemic Stroke and Atrial Fibrillation Taking Anticoagulants.
PubMed 文献 · Stroke · 2020-10-08

本研究纳入1742例口服抗凝药的房颤急性缺血性卒中患者,分析脑微出血对2年主要不良心脑血管事件的影响。调整混杂因素后,微出血存在与事件风险相关(HR 1.89,95%CI 1.23-2.88,P=0.003)。单发微出血与无微出血事件率相似,多发(≥2)尤其高负荷(≥5)微出血事件比例显著更高;华法林治疗者中微出血与事件风险显著相关,直接口服抗凝药者中不显著。

要点

  • 脑微出血存在与口服抗凝的房颤卒中患者2年主要不良心脑血管事件风险独立相关。
  • 单发微出血事件风险与无微出血相似,多发尤其≥5个微出血事件风险显著升高。
  • 微出血部位(脑叶或深部)不影响事件风险,华法林治疗者中关联更明显。

核心结论

  • 在口服抗凝药的房颤急性缺血性卒中患者中,未来主要不良心脑血管事件风险随脑微出血负荷增加而升高。
  • 脑微出血解剖部位不影响未来主要不良心脑血管事件风险。
  • 该风险在华法林治疗患者中似乎更明显。

研究设计与样本

  • 队列研究,纳入1742例口服抗凝药治疗的房颤急性缺血性卒中患者。
  • 主要复合结局为2年内主要不良心脑血管事件(卒中、急性心肌梗死或血管性死亡)。

主要发现

  • 调整混杂因素后,脑微出血存在与主要不良心脑血管事件风险显著相关(HR 1.89,95%CI 1.23-2.88,P=0.003)。
  • 恰好1个微出血者主要不良心脑血管事件率与无微出血者相似(P=0.461)。
  • 多发微出血(≥2)尤其高负荷微出血(≥5)者主要不良心脑血管事件比例显著更高。
  • 脑叶和深部微出血阳性组主要不良心脑血管事件均多于微出血阴性组,事件率不因部位不同而异。
  • 华法林治疗者中微出血与主要不良心脑血管事件风险显著相关(P=0.002),直接口服抗凝药治疗者中不显著(P=0.517)。

临床怎么用

  • 对口服抗凝药的房颤急性缺血性卒中患者,评估脑微出血数目有助于分层主要不良心脑血管事件风险。
  • 多发尤其≥5个微出血提示事件风险更高,华法林治疗者中关联更明显。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: We investigated the impact of the presence, burden, and location of cerebral microbleeds (CMBs) on the risk of major adverse cerebrovascular and cardiovascular events (MACCE) in patients with acute ischemic stroke and atrial fibrillation treated with oral anticoagulants (OACs). We also examined whether the clinical effect of CMBs differs according to the type of OACs. METHODS: A total of 1742 patients with acute ischemic stroke and atrial fibrillation treated with OACs were enrolled in this cohort study. The primary composite outcome was the occurrence of MACCE (a composite of stroke, acute myocardial infarction, or vascular death) over a 2-year period according to CMB status. RESULTS: CMB presence was significantly associated with the risk of future MACCE (hazard ratio, 1.89 [95% CI, 1.23-2.88]; P=0.003) after adjustment for confounders in patients with acute ischemic stroke and atrial fibrillation taking OACs. Patients with exactly 1 CMB had a similar rate of MACCE compared with those without CMBs (P=0.461). However, patients with multiple CMBs (≥2), particularly high burden CMBs (≥5), had a significantly higher proportion of MACCE. Both CMB-positive groups with lobar and deep CMB had more frequent MACCE than the CMB-negative group, and the rate of MACCE was not different according to CMB location. In patients treated with warfarin, CMB was significantly associated with a risk of MACCE (P=0.002), but not in patients treated with direct OACs (P=0.517). CONCLUSIONS: The study results indicate that the risk of future MACCE increased with increasing CMB burden in patients with AIS and atrial fibrillation taking OACs, while the anatomic location of CMBs did not influence the risk of future MACCE. This risk seemed to be more apparent in patients taking warfarin.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Choi KH, Kim JH, Lee C, et al. Microbleeds and Outcome in Patients With Acute Ischemic Stroke and Atrial Fibrillation Taking Anticoagulants. Stroke. 2020. PMID: 33028171. doi:10.1161/STROKEAHA.120.030300

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。